Uniqure (QURE) – Analysts’ Recent Ratings Updates

Posted by Max Byerly on Apr 9th, 2018 // No Comments

Several analysts have recently updated their ratings and price targets for Uniqure (NASDAQ: QURE):

4/7/2018 – Uniqure was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
4/4/2018 – Uniqure was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
4/2/2018 – Uniqure was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
3/24/2018 – Uniqure was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
3/20/2018 – Uniqure had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott. They now have a $30.00 price target on the stock.
3/17/2018 – Uniqure was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
3/15/2018 – Uniqure was given a new $35.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
2/24/2018 – Uniqure was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
2/20/2018 – Uniqure was given a new $35.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
2/10/2018 – Uniqure was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of NASDAQ QURE opened at $21.96 on Monday. Uniqure NV has a 1-year low of $4.72 and a 1-year high of $27.19. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.46 and a current ratio of 8.46. The company has a market cap of $695.78, a PE ratio of -7.47 and a beta of 0.18.

How to Become a New Pot Stock Millionaire

Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.23). Uniqure had a negative return on equity of 174.25% and a negative net margin of 604.72%. The company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $2.83 million. equities research analysts predict that Uniqure NV will post -3.21 earnings per share for the current year.

In other Uniqure news, insider Deventer Sander Van sold 5,985 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $18.53, for a total transaction of $110,902.05. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 39,169 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $21.72, for a total value of $850,750.68. Following the transaction, the chief executive officer now owns 439,764 shares in the company, valued at approximately $9,551,674.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,032 shares of company stock worth $1,014,982. Corporate insiders own 0.73% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of Uniqure in the 4th quarter valued at $119,000. Ellington Management Group LLC acquired a new stake in shares of Uniqure in the 4th quarter valued at $237,000. Goldman Sachs Group Inc. acquired a new stake in shares of Uniqure in the 4th quarter valued at $373,000. Virtus Fund Advisers LLC acquired a new stake in shares of Uniqure during the 4th quarter valued at $389,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Uniqure during the 3rd quarter valued at $399,000. Hedge funds and other institutional investors own 42.76% of the company’s stock.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.

Receive News & Ratings for Uniqure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure NV and related companies with MarketBeat.com's FREE daily email newsletter.